Find the latest news about Inaphaea BioLabs here
This month marks one year since Inaphaea BioLabs launched. In this blog, Dr Andrew Carnegie, Head of Strategic Commercial Development at Inaphaea, describes how Inaphaea has grown and developed during its first…
This news round-up covers our updates from March. BioEurope was a key highlight, with our commercial team conducting over 60 meetings and spreading the word about Inaphaea to the wider market. To…
Inaphaea prides itself on conducting science that is reproducible, human-relevant, and translatable to ensure efficient progress through discovery and preclinical development. Patient-derived cells (PDCs) are at the heart of Inaphaea’s work and…
Drug discovery is known for its high attrition rates that lead to significant investments of both cost and time. But the emergence of patient-derived cells (PDCs) is on track to revolutionise this…
This news round-up covers our updates and highlights from January and February. It has been a busy start to the year for Inaphaea with events, a new collaboration, and progress in the…
The International Day of Women and Girls in Science is an annual event celebrated on 11 February and promotes the full and equal access and participation of women in Science, Technology, Engineering,…
2023 saw the launch of Inaphaea and we’re delighted to report that the company is continuing to go from strength to strength. With a strong and dedicated scientific and commercial team, and…
This roundup covers our news, updates, and highlights from October. This month was another busy one for the team, seeing us attend ELRIG Drug Discovery – a flagship event in the drug…
In September, Inaphaea BioLabs welcomed two students from the University of Nottingham to undertake a two-week placement in the lab. The students, Daniel Abegunde and Jozaine Fenton, received a hands-on placement experience…
In recognition of Ada Lovelace Day, Inaphaea’s Zai Ahmad shares her journey into STEM, discusses the landscape shifts she has seen within secondary education, and highlights the changes that still need to…